Company news

Invion Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ph 2 Prostate Cancer Results Strong Safety and 40% Response

September 17, 2024

Invion secures funding through an institutional placement

June 27, 2024

Agreement with Major South Korean Pharma Group Hanlim

May 7, 2024

INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC

March 4, 2024

Agreement with Dr.inB to develop Photosoft treatment for HPV

February 22, 2024

AGM Presentation

November 28, 2023

Major Milestone towards Clinical Trials

November 21, 2023

Investor Presentation

October 23, 2023

Photosoft Territory Expanded to South Korea for Cancer

September 24, 2023

Appendix 4E and Preliminary Financial Report

August 30, 2023

Expansion of Territory Rights to USA, Canada and Hong Kong

February 7, 2023

INV043 Effective Against Anal Cancer SCC In Vitro

September 14, 2022

Response to ASX Aware Query

September 13, 2022

Photosoft Shows Activity Against Zika Virus

September 7, 2022

Activities Report and Appendix 4C

July 20, 2022

INV043 significantly improved checkpoint inhibitor therapy

May 29, 2022

Supplementary Prospectus

November 25, 2021

Prospectus

November 22, 2021

Share Purchase Plan Offer Booklet & Application Form

November 21, 2021

Capital Raising and expansion of Photosoft Territory

November 16, 2021

Further Information on Proof of Concept Pilot Study

October 28, 2021

Complete Regression of TNBC Tumours and Protective Immunity

October 27, 2021

Capital Raising & co-development for Photosoft Technology

June 2, 2021

Initial Proof-of-Concept results show INV043 to be effective

May 24, 2021

App 4D and Financial Report for half year to 31 Dec 2020

February 24, 2021

Business Update and Change to Board and Management

July 28, 2020

Activities Report and Appendix 4C June 2020 Quarter

July 28, 2020

Invion subsidiary signs Supply Agreement with Pavay Biotech

June 30, 2020

Appendix 4C - March 2020 quarter

April 20, 2020

App 4D and Financial Report for half year to 31 Dec 2019

February 24, 2020

Invion signs R&D Services Agreement with Pavay Biotech

February 2, 2020

Appendix 4C - December 2019 quarter

January 29, 2020

Additional Information to Prior Announcement

November 28, 2019

Pre-clinical research agreement with Peter MacCallum CC

October 30, 2019

Appendix 4C - September 2019 quarter

October 28, 2019

Appendix 4E and Financial Report for year ended 30 June 2019

August 28, 2019

COO Craig Newton to transition to Invion CEO

July 21, 2019

Appendix 4C - June quarter

July 12, 2019

Animal studies show IVX-P02 potential in metastatic cancers

May 27, 2019

Quarterly Update

April 17, 2019

Appendix 4D and Financial Report for Half Year to 31 Dec 18

February 26, 2019

Response to ASX Appendix 4C Query

February 20, 2019

Invion completes spin-out of respiratory assets

February 11, 2019

General Meeting - Results of Meeting

January 30, 2019

Appendix 4C - December quarter

January 28, 2019

Appendix 4C - September 2018 quarter

October 28, 2018

New Photosoft formulation increased effect in ovarian cancer

September 24, 2018

Spin out of respiratory assets for development in China

September 4, 2018

Appendix 4E Annual Report and Full Year Statutory Accounts

August 28, 2018

Appendix 4C - June 2018 quarter

July 27, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 43 decks. Every deck is listed under its year.